RPRX
Royalty Pharma plc - Ordinary Shares - Class A

7,313
Loading...
Loading...
News
all
press releases
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Royalty Pharma (RPRX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks·1mo ago
News Placeholder
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Sector ETF report for IHE
Zacks·2mo ago
News Placeholder
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma
Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured loan of up to $750 million.
Stocktwits·3mo ago
News Placeholder
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street
These biotech companies’ strategic advancements are setting them up for long-term success.
barchart.com·7mo ago
News Placeholder
2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall Street
The recent advancements in their pipelines imply high growth potential in the coming years.
barchart.com·7mo ago
News Placeholder
Insights Ahead: Royalty Pharma's Quarterly Earnings
read more...
Benzinga·10mo ago
News Placeholder
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement...
PR Newswire·10mo ago

Latest RPRX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.